Ponvory (ponesimod) - Juvise Pharma, Vanda
Zeposia (ozanimod) - BMS
Velsipity (etrasimod) - Pfizer
fingolimod - Generic mfg.
siponimod - Generic mfg.
Ocular safety signals of sphingosine-1-phosphate receptor modulators in postmarketing surveillance. (PubMed, Front Pharmacol) - Oct 11, 2026 - "Fingolimod had the broadest signal spectrum; macular oedema was the principal anatomically specific signal for siponimod and ozanimod. No ponesimod PT met primary criteria, and the etrasimod macular oedema estimate was sparse (n = 11)...The association remained evident after phenotype aggregation and indication-restricted analysis and was also observed in Canada Vigilance. Sparse data for newer agents and residual confounding limit comparative interpretation." 
Journal • P4 data • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Macular Edema • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Ulcerative Colitis
http://www.ncbi.nlm.nih.gov/pubmed/42856682
 
Jie Zhang; Jing Han; Jue Wang; Mei Fu; Nan Ma; Qingyi He; Yangjun Li
 
Oct 11, 2026
 
Prev Next